Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Report Date: July 16, 2026
Event: Announcement of Second Quarter 2026 results of operations.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results have been announced and refers to an attached news release (Exhibit 99.1) for detailed figures.
Non-GAAP Measures: The company utilizes non-GAAP financial measures to assess performance, excluding:
- Acquisition-related expenses
- Legal reserves and restructuring actions
- Stock-based compensation accelerated in connection with acquisitions
- Certain regulatory costs and tax adjustments
- Intangible amortization expense
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the incorporated news release for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures provide useful information for evaluating ongoing business performance and are used internally to monitor business units. However, the company cautions that these measures should be considered in addition to, and not as a substitute for, GAAP financial measures.
Risks and Contingencies: The text does not explicitly detail new risks or contingencies beyond the standard caution regarding the use of non-GAAP measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net earnings, and cash flow figures.
- Compare reported GAAP results against the non-GAAP adjustments listed to understand the impact of one-time items.
- Verify the specific components of "specified items" excluded from net earnings to assess the quality of earnings.
- Check for any updated full-year guidance provided in the referenced news release.